Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pregnancy exposure registries.

Dianne L Kennedy1, Kathleen Uhl, Sandra L Kweder

  • 1Pregnancy Labeling Task Force, US Food and Drug Administration, Rockville, Maryland 20874, USA. kennedyd@cder.fda.gov

Drug Safety
|March 9, 2004
PubMed
Summary

Collecting reliable data on drug safety during pregnancy is crucial. Post-marketing pregnancy registries with rigorous methods are essential for monitoring fetal effects and informing patient care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?

Clinical pharmacology and therapeutics·2019
Same author

A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why.

Clinical pharmacology and therapeutics·2019
Same author

Generic Drugs: Expanding Possibilities for Clinical Pharmacology.

Clinical pharmacology and therapeutics·2019
Same author

How the FDA Ensures High-Quality Generic Drugs.

American family physician·2018
Same author

Regional Approaches to Expedited Drug Development and Review: Can Regulatory Harmonization Improve Outcomes?

Therapeutic innovation & regulatory science·2018
Same author

Prioritization of Generic Drug Review.

JAMA internal medicine·2016

Area of Science:

  • Pharmacovigilance
  • Reproductive Toxicology
  • Public Health

Background:

  • Limited human data on fetal drug effects during pregnancy necessitates better safety monitoring.
  • Animal studies offer preliminary insights but cannot fully predict human teratogenicity.
  • Pregnant women are frequently exposed to medications, underscoring the need for safety information.

Purpose of the Study:

  • To highlight the critical need for scientifically valid data on drug safety in human pregnancies.
  • To emphasize the inadequacy of passive adverse event reporting for detecting drug-induced fetal risks.
  • To advocate for the development and implementation of rigorous, epidemiologically sound pregnancy exposure registries.

Main Methods:

  • Discusses the limitations of existing data sources, including animal studies and spontaneous reporting.
  • Proposes post-marketing pregnancy exposure registries as a proactive surveillance method.
  • Stresses the importance of methodologically sound protocols, adequate recruitment, aggressive follow-up, and accurate outcome ascertainment for registries.

Main Results:

  • Existing methods for assessing drug safety in pregnancy are insufficient for clinical decision-making.
  • Post-marketing pregnancy exposure registries are increasingly vital for monitoring fetal outcomes.
  • Methodological rigor is paramount for generating reliable data from these registries.

Conclusions:

  • Rigorous, well-designed pregnancy exposure registries are essential for ensuring drug safety during pregnancy.
  • High-quality data from these registries are critical for healthcare providers to counsel patients effectively.
  • Proactive, systematic monitoring is necessary to detect or confirm the absence of drug-induced fetal effects.

Related Experiment Videos